{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:24:52Z","timestamp":1762917892409,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Chinese National Science and Technology Major Project","award":["2017ZX10105015001002"],"award-info":[{"award-number":["2017ZX10105015001002"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.vaccine.2018.05.075","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T09:05:13Z","timestamp":1528103113000},"page":"4354-4361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intranasal inoculate of influenza virus vaccine against lethal virus challenge"],"prefix":"10.1016","volume":"36","author":[{"given":"Xueting","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiudong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yening","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengli","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2018.05.075_b0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1128\/JVI.01812-10","article-title":"T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model","volume":"85","author":"Guo","year":"2011","journal-title":"J Virol"},{"issue":"20","key":"10.1016\/j.vaccine.2018.05.075_b0010","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.2174\/15680266113136660183","article-title":"Vaccine adjuvants: key tools for innovative vaccine design","volume":"13","author":"Riese","year":"2013","journal-title":"Curr Topics Med Chem"},{"issue":"7","key":"10.1016\/j.vaccine.2018.05.075_b0015","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.nano.2017.05.012","article-title":"Intranasal vaccination with an adjuvanted polyphosphazenes nanoparticle-based vaccine formulation stimulates protective immune responses in mice","volume":"13","author":"Schulze","year":"2017","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.075_b0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00253-004-1874-1","article-title":"Influenza vaccines: recent advances in production technologies","volume":"67","author":"Bardiya","year":"2005","journal-title":"Appl Microbiol Biotechnol"},{"issue":"10","key":"10.1016\/j.vaccine.2018.05.075_b0025","first-page":"3273","article-title":"Toward a broadly protective influenza vaccine","volume":"118","author":"Doherty","year":"2008","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.075_b0030","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol Cell Biol"},{"issue":"8","key":"10.1016\/j.vaccine.2018.05.075_b0035","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2018.05.075_b0040","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.vaccine.2016.01.020","article-title":"The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine","volume":"34","author":"Saito","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.05.075_b0045","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/21645515.2016.1278098","article-title":"Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines","volume":"13","author":"Wu","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.075_b0050","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.vaccine.2005.08.061","article-title":"The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection","volume":"24","author":"De Filette","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.075_b0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-3083.2005.01713.x","article-title":"The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization","volume":"63","author":"Akhiani","year":"2006","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2018.05.075_b0060","doi-asserted-by":"crossref","unstructured":"Pedersen G, Cox R. The mucosal vaccine quandary: intranasal vs. sublingual immunization against influenza. Hum Vaccin Immunother 2012;8(5):689\u201393. http:\/\/doi.org\/10.4161\/hv.19568","DOI":"10.4161\/hv.19568"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.075_b0065","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1051\/vetres:2006014","article-title":"Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa","volume":"37","author":"Cox","year":"2006","journal-title":"Vet Res"},{"issue":"10","key":"10.1016\/j.vaccine.2018.05.075_b0070","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/17425247.2014.931936","article-title":"Intranasal formulations: promising strategy to deliver vaccines","volume":"11","author":"Riese","year":"2014","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.vaccine.2018.05.075_b0075","first-page":"1","article-title":"Adjuvanted influenza vaccines","volume":"12","author":"Tregoning","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.075_b0080","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1086\/315337","article-title":"Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant","volume":"181","author":"Gl\u00fcck","year":"2000","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.075_b0085","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0952-7915(02)00384-9","article-title":"Recent advances in mucosal vaccines and adjuvants","volume":"14","author":"Eriksson","year":"2002","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.075_b0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1128\/iai.29.1.91-97.1980","article-title":"Properties of homogeneous heat-labile enterotoxin from Escherichia coli","volume":"29","author":"Clements","year":"1980","journal-title":"Infect Immunity"},{"issue":"10","key":"10.1016\/j.vaccine.2018.05.075_b0095","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1128\/iai.61.10.4272-4279.1993","article-title":"Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant","volume":"61","author":"Jackson","year":"1993","journal-title":"Infect Immunity"},{"issue":"9","key":"10.1016\/j.vaccine.2018.05.075_b0100","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/eji.1830220915","article-title":"The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxinsis linked to their ADP-ribosyltransferase activity","volume":"22","author":"Lycke","year":"1992","journal-title":"Euro J Immunol"},{"issue":"17\u201319","key":"10.1016\/j.vaccine.2018.05.075_b0105","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/S0264-410X(00)00553-3","article-title":"Mucosal vaccines non toxic derivatives of LT and CT as mucosal adjuvants","volume":"19","author":"Pizza","year":"2001","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.075_b0110","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1128\/IAI.01559-08","article-title":"Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes","volume":"77","author":"Negri","year":"2009","journal-title":"Infect Immunity"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.075_b0115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/iai.43.2.515-522.1984","article-title":"Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine","volume":"43","author":"Levine","year":"1984","journal-title":"Infect Immunity"},{"issue":"9","key":"10.1016\/j.vaccine.2018.05.075_b0120","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell\u2019s palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"New England J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2018.05.075_b0125","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.4049\/jimmunol.158.8.3936","article-title":"Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit","volume":"158","author":"Agren","year":"1997","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.075_b0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1462-5822.2003.00338.x","article-title":"From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD\/ISCOM","volume":"6","author":"Lycke","year":"2004","journal-title":"Cell Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.075_b0135","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1128\/IAI.01290-06","article-title":"The combined CTA1-DD\/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis","volume":"75","author":"Andersen","year":"2007","journal-title":"Infect Immunity"},{"issue":"9","key":"10.1016\/j.vaccine.2018.05.075_b0140","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.vaccine.2007.12.027","article-title":"CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine","volume":"26","author":"Eliasson","year":"2008","journal-title":"Vaccine"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2018.05.075_b0145","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1099\/vir.0.2008\/005470-0","article-title":"CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization","volume":"89","author":"Sundling","year":"2008","journal-title":"J Gen Virol"},{"issue":"22","key":"10.1016\/j.vaccine.2018.05.075_b0150","doi-asserted-by":"crossref","first-page":"11374","DOI":"10.1128\/JVI.01176-08","article-title":"Pathogenicity and vaccine efficacy of different clades of Asian H5N1 avian influenza A viruses in domestic ducks","volume":"82","author":"Kim","year":"2008","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2018.05.075_b0155","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0264-410X(96)00287-3","article-title":"Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants","volume":"15","author":"Benne","year":"1997","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.075_b0160","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1086\/314952","article-title":"Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection","volume":"180","author":"Moran","year":"1990","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2018.05.075_b0165","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/CVI.00156-06","article-title":"Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza","volume":"13","author":"Huber","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"30","key":"10.1016\/j.vaccine.2018.05.075_b0170","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1016\/j.vaccine.2017.05.053","article-title":"Nontoxic outer membrane vesicles efficiently increase the efficacy of an influenza vaccine in mice and ferrets","volume":"35","author":"Shim","year":"2007","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.05.075_b0175","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cid\/cis211","article-title":"Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993\u20132008","volume":"54","author":"Zhou","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"46","key":"10.1016\/j.vaccine.2018.05.075_b0180","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1016\/j.vaccine.2014.08.068","article-title":"Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children","volume":"32","author":"Nolan","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.075_b0185","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2010.222","article-title":"Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses","volume":"19","author":"Torrieri-Dramard","year":"2011","journal-title":"Mol Therapy J Am Soc Gene Therapy"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2018.05.075_b0190","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2004.02.021","article-title":"Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys","volume":"22","author":"Fan","year":"2004","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.075_b0195","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jcv.2004.09.013","article-title":"Intranasal immunization with liposome-encapsulated plasmid dna encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses","volume":"31","author":"Wang","year":"2004","journal-title":"J Clin Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.075_b0200","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00705-010-0621-4","article-title":"Cross-protection against influenza virus infection by intranasal administration of m2-based vaccine with chitosan as an adjuvant","volume":"155","author":"Sui","year":"2010","journal-title":"Arch Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2018.05.075_b0205","doi-asserted-by":"crossref","first-page":"e24626","DOI":"10.1371\/journal.pone.0024626","article-title":"Cross-protective peptide vaccine against influenza a viruses developed in hla-a*2402 human immunity model","volume":"6","author":"Ichihashi","year":"2011","journal-title":"Plos One"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.075_b0210","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.4049\/jimmunol.173.5.3310","article-title":"The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues","volume":"173","author":"Eriksson","year":"2004","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.075_b0215","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.4049\/jimmunol.1002881","article-title":"A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development","volume":"186","author":"Bemark","year":"2011","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2018.05.075_b0220","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.4049\/jimmunol.176.6.3697","article-title":"The combined CTA1-DD\/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells","volume":"176","author":"Helgeby","year":"2006","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.075_b0225","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jri.2009.04.002","article-title":"CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa","volume":"81","author":"Cunningham","year":"2009","journal-title":"J Reprod Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.075_b0230","first-page":"767","article-title":"The role of serum haemagglutinationinhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J Hygiene"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.075_b0235","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/vaccines2040707","article-title":"Overview of serological techniques for influenza vaccine evaluation: past, present and future","volume":"2","author":"Trombetta","year":"2014","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.075_b0240","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1084\/jem.185.5.941","article-title":"Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes","volume":"185","author":"Dubois","year":"1997","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2018.05.075_b0245","doi-asserted-by":"crossref","first-page":"e0128785","DOI":"10.1371\/journal.pone.0128785","article-title":"Intranasal immunization with pressure inactivated avian influenza elicits cellular and humoral responses in mice","volume":"10","author":"Barroso","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.075_b0250","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1128\/iai.60.5.1786-1792.1992","article-title":"Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium","volume":"60","author":"Michetti","year":"1992","journal-title":"Infect Immunity"},{"issue":"6","key":"10.1016\/j.vaccine.2018.05.075_b0255","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/jir.2009.0084","article-title":"IFN-gamma treatment at early stages of influenza virus infection protects mice from death in a nk cell-dependent manner","volume":"30","author":"Weiss","year":"2010","journal-title":"J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:26:48Z","timestamp":1759400808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18307394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":51,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0264410X18307394"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal inoculate of influenza virus vaccine against lethal virus challenge","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}